AML Part 3

Learning Objectives

  • Understand treatment for adult AML patients unfit for intensive chemotherapy
  • Understand IDH mutations as a target in AML and treatment
  • Understand FLT3 mutations as a target in AML and treatment
Course summary
Available credit: 
  • 1.00 ACPE - Pharmacist
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 JA Credit - AH
    • 1.00 Approved for AMA PRA Category 1 Credit(s)™
Registration Opens: 
01/16/2020
Registration Expires: 
01/15/2022
Part of: 
Advanced Practice Provider Webinar Lecture Series 2020
Rating: 
0

Available Credit

  • 1.00 ACPE - Pharmacist
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 JA Credit - AH
    • 1.00 Approved for AMA PRA Category 1 Credit(s)™
Please login or register to take this course.